4.2 Article

Risperidone and Lorazepam Concomitant Use in Clonazepam Refractory Catatonia A Case Report

期刊

JOURNAL OF NERVOUS AND MENTAL DISEASE
卷 199, 期 12, 页码 987-988

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/NMD.0b013e3182392d7e

关键词

Catatonia; schizophrenia; risperidone; refractory; lorazepam

资金

  1. Astra Zeneca
  2. Merck/Bristol Myers Squibb

向作者/读者索取更多资源

The DSM-IV recognizes catatonia as a subtype of schizophrenia characterized by at least two of the following: motor immobility, excessive motor activity not influenced by external stimuli, and peculiarities of voluntary movement. Catatonia may also occur secondary to mania, depression, or a general medical condition including encephalitis, focal neurological lesions, metabolic disturbances, and drug intoxications and withdrawals. Benzodiazepines remain the first line of treatment; up to 80% of patients respond promptly to Lorazepam challenge; failure to respond to lorazepam may be followed by electroconvulsive therapy. Atypical antipsychotics may be a new alternative in the treatment of catatonia. Successful reduction of the catatonic symptoms has been demonstrated with atypical antipsychotics. A possible mechanism of action for the efficacy of this class of drugs involves the antagonism of the 5-HT2A receptor. We are now reporting a case of treatment response to risperidone in a patient with chronic catatonia resistant to benzodiazepines.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据